Literature DB >> 15785094

Heparin regulates transcription of endothelin-1 gene in endothelial cells.

Kazue Kuwahara-Watanabe1, Chiaki Hidai, Hiromi Ikeda, Yoshikazu Aoka, Ken-ichiro Ichikawa, Nobuo Iguchi, Masako Okada-Ohno, Jinko Yokota, Hiroshi Kasanuki, Masatoshi Kawana.   

Abstract

Heparin, which is widely used as an anticoagulant, has been shown to have antiatherosclerotic and antihypertensive effects in animals and humans. These effects are mediated by the inhibition of endothelin-1 (ET-1) production in endothelial cells. To clarify the mechanism of this inhibition, we investigated the effect of heparin on transcriptional regulation of the ET-1 gene in bovine aortic endothelial cells (BAEC) cultured in fetal calf serum. ET-1 mRNA expression was significantly suppressed by heparin in a dose-dependent manner. Promoter analysis revealed that the minimum ET-1 promoter containing only the GATA and AP-1 sequences as positive cis-acting sites in the ET-1 promoter is sufficient for this suppression. Gel mobility shift assays using oligonucleotides encoding the ET-1 AP-1 and ET-1 GATA sites confirmed that both AP-1 and GATA binding activities in BAEC nuclear extract were markedly inhibited by heparin. Western blot analyses indicated that heparin completely blocked extracellular signal-regulated kinase (ERK) activation, and inhibiting ERK activity resulted in loss of heparin-dependent inhibition of the ET-1 gene. These data indicate that the ET-1 mRNA level is negatively regulated by heparin at the transcription level, through modification of AP-1 and GATA protein binding activities, which direct the ET-1 promoter in BAEC. This effect may be mediated, at least in part, through inhibition of ERK activity. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15785094     DOI: 10.1159/000084656

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  6 in total

Review 1.  Endothelin-1 gene regulation.

Authors:  Lisa R Stow; Mollie E Jacobs; Charles S Wingo; Brian D Cain
Journal:  FASEB J       Date:  2010-09-13       Impact factor: 5.191

Review 2.  Unfractionated heparin: multitargeted therapy for delayed neurological deficits induced by subarachnoid hemorrhage.

Authors:  J Marc Simard; David Schreibman; E Francois Aldrich; Bernadette Stallmeyer; Brian Le; Robert F James; Narlin Beaty
Journal:  Neurocrit Care       Date:  2010-12       Impact factor: 3.210

3.  Low-dose intravenous heparin infusion in patients with aneurysmal subarachnoid hemorrhage: a preliminary assessment.

Authors:  J Marc Simard; E Francois Aldrich; David Schreibman; Robert F James; Adam Polifka; Narlin Beaty
Journal:  J Neurosurg       Date:  2013-09-13       Impact factor: 5.115

4.  Heparin reduces neuroinflammation and transsynaptic neuronal apoptosis in a model of subarachnoid hemorrhage.

Authors:  J Marc Simard; Cigdem Tosun; Svetlana Ivanova; David B Kurland; Caron Hong; Leanne Radecki; Carter Gisriel; Rupal Mehta; David Schreibman; Volodymyr Gerzanich
Journal:  Transl Stroke Res       Date:  2012-04-14       Impact factor: 6.829

5.  Circulating Biomarker Levels in Patients With Stage 5 Chronic Kidney Disease With Respect to Neurovascular Diseases.

Authors:  Justin Lee; Ryan McMillan; Leonidas Skiadopoulos; Vinod Bansal; José Biller; Debra Hoppensteadt; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2018-11-14       Impact factor: 2.389

Review 6.  Heparin: The Silver Bullet of Aneurysmal Subarachnoid Hemorrhage?

Authors:  Nicolas K Khattar; Robert F James
Journal:  Front Neurol       Date:  2018-03-27       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.